07-Nov-2026 18:32:39
DIVI'S LABORATORIES Q2 FY27 CONCALL: MAINTAINS 32–35% EBITDA MARGIN GUIDANCE DESPITE ~40% H1 MARGINS; EXPECTS DOUBLE-DIGIT H2 REVENUE GROWTH, 3 CUSTOM SYNTHESIS PROJECTS NEARING COMMERCIALIZATION & ₹2,000 CR ANNUAL CAPEX
DIVI'S LABORATORIES Q2 FY27 CONCALL: MAINTAINS 32–35% EBITDA MARGIN GUIDANCE DESPITE ~40% H1 MARGINS; EXPECTS DOUBLE-DIGIT H2 REVENUE GROWTH, 3 CUSTOM SYNTHESI…